Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

High-Coordination Single-Atom Nanozyme-Based Colorimetric-Photothermal Sensing Platform for Evaluation of Total Antioxidant Capacity.

Analytical chemistry·2026
Same author

High-throughput protein target mapping enables accelerated bioactivity discovery for ToxCast and PFAS compounds.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Deep learning prediction of pathological complete response in breast cancer using Mamba architecture.

NPJ digital medicine·2026
Same author

A hybrid preprocessing strategy-based NIR spectroscopy method for rapid determination of nutritional components in Cyperus esculentus with SHAP interpretation.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026
Same author

Development of NanoBRET cellular target engagement assays in primary neurons for activating mutants of p21-activated kinase 1.

bioRxiv : the preprint server for biology·2026
Same author

Large-scale discovery, analysis and design of protein energy landscapes.

Nature·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

U Hang Chan1,2, Fengling Li2, Frances M Bashore3,4

  • 1University of Toronto, Toronto, ON, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Los investigadores desarrollaron un nuevo ensayo para encontrar inhibidores de moléculas pequeñas para las helicasas de ARN MDA5, LGP2 y DDX1, que están relacionadas con el Alzheimer

Palabras clave:
helicasas de ARNinhibidores de moléculas pequeñasEnfermedad de AlzheimerMDA5LGP2DDX1ensayo de cribadodesarrollo de fármacos

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Sus antecedentes:

  • El descubrimiento de fármacos para la enfermedad de Alzheimer (EA) requiere nuevos objetivos más allá de la amiloide y la tau.
  • El análisis bioinformático identificó las helicasas de ARN MDA5, LGP2 y DDX1 como genes de riesgo de EA de alta prioridad.
  • Estas helicasas participan en la inmunidad innata y tienen vínculos potenciales con la patología de la EA.

Objetivo del estudio:

  • Desarrollar nuevas sondas químicas de molécula pequeña dirigidas a MDA5, LGP2 y DDX1.
  • Elucidar el papel de estas helicasas de ARN en la patogénesis de la enfermedad de Alzheimer.
  • Establecer un ensayo de cribado de alto rendimiento para identificar inhibidores de estas dianas.

Principales métodos:

  • Desarrollo de un ensayo de ATPasa basado en bioluminiscencia para la caracterización cinética.
  • Se utilizó el cribado de bibliotecas químicas codificadas con ADN (DEL) para el descubrimiento de éxitos de moléculas pequeñas.
  • Confirmación de éxitos mediante ensayos de ATPasa, SPR, DSF y RMN de 19F.

Principales resultados:

  • Se estableció un ensayo robusto de alto rendimiento para el cribado de inhibidores de MDA5, LGP2 y DDX1.
  • Se identificó un inhibidor selectivo de MDA5 mediante el cribado DEL-ML con una IC50 de 8 µM.
  • El inhibidor identificado se confirmó ortogonalmente y sirve como punto de partida para el descubrimiento de fármacos.

Conclusiones:

  • El ensayo desarrollado permite el cribado y la optimización eficientes de inhibidores de moléculas pequeñas.
  • Se descubrió un inhibidor de molécula pequeña de primera clase para MDA5.
  • Este inhibidor puede utilizarse para investigar más a fondo el papel de MDA5 en la enfermedad de Alzheimer.